Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DOI

10.1111/tri.12139

Type

Journal article

Journal

Transpl Int

Publication Date

10/2013

Volume

26

Pages

e91 - e93

Keywords

Alemtuzumab, Antibodies, Monoclonal, Humanized, Female, Graft Survival, HLA Antigens, Humans, Immunosuppressive Agents, Infection, Inflammation, Intestinal Mucosa, Intestine, Small, Intestines, Mesenchymal Stem Cell Transplantation, Mesenchymal Stromal Cells, Middle Aged, Neuromuscular Diseases, Postoperative Complications, Regeneration, Short Bowel Syndrome, Tacrolimus, Transplantation, Treatment Outcome